

Index

Note: Page numbers of article titles are in **boldface** type.

A

- Aflibercept, 338
- O⁶-Alkylguanine-DNA alkyltransferase, 314
- Angiogenesis inhibitors, 281–282, 338. *See also* Bevacizumab.
- Angiogenic switch, 332
- Anisotropic diffusion sensor imaging, for eloquent gliomas, 220–221
- Antiangiogenic therapy, 281–282, 338. *See also* Bevacizumab.
- Antiepileptic drugs, 230–231, 299
- Aphasia, after insular glioma resection, 204
- Arcuate fasciculus, injury of, in insular surgery, 204
- Avastin. *See* Bevacizumab.

B

- Bartholow, Robert, on brain function, 216
- Base excision repair, inhibitors of, 314
- BCNU (carmustine, Gliadel) polymer wafers, **289–295**, 302–303
 - animal studies of, 289–290
 - approval of, 315–316
 - clinical trials of, 290–292
 - combination trials with, 293
 - limitations of, 290, 293
 - pharmacokinetics of, 289–290
- Bevacizumab, 261, 277, 280, 293, **331–341**
 - adverse effects of, 335
 - angiogenesis mechanisms in, 332–334
 - approval of, 315–316
 - clinical trials of, 334–335
 - efficacy of, 335–338
 - for glioblastoma, 281–282
 - for multifocal and multicentric gliomas, 236
 - for radiation necrosis, 339
 - intra-arterial infusion of, **323–329**, 338–339
 - irinotecan with, 300
 - treatment after, 336–337
 - versus other antiangiogenic drugs, 338
- Brain mapping, for eloquent gliomas, **215–225**
- Brain Tumor Cooperative Group trials, of radiation therapy, 260
- Bromodeoxyuridine, 250

C

- Carbamazepine, for seizures, 231
- Carbon ions, with high linear energy transfer-charged particle therapy, 263

- Carmustine (BCNU, Gliadel) polymer wafers, **289–295**, 302–303, 315–316
- CCNU (lomustine), 289, 300–302
- Cediranib, 338
- Central sulcus, electrocortical mapping of, 218–219
- Ceramide synthase, in radiation necrosis, 280–281
- Cerebral artery, middle, anatomy of, 200
- Cerebral infusions, supraselective intra-arterial, **323–329**, 338–339
- Cerebrospinal fluid, drugs directed to, 347–348
- Cetuximab, 230–231, **323–329**
- Charged particle therapy, 252–253
- Chemotherapy. *See also specific agents.*
 - antiepileptic drug interactions with, 231
 - for multifocal and multicentric gliomas, 345–348
 - for seizures, 229–230
 - intra-arterial infusion of, **323–329**, 338–339
 - monoclonal antibodies attached to, 239
 - radiation therapy with, 260–261, 263
- Cilengitide, 315, 338, 347
- CINDERELLA trial, 263
- Cisplatin, 297–298
- Computed tomography
 - for determining treatment response, 269–270, 272
 - for surgical planning, 261–262
- Conformal radiotherapy, for multifocal and multicentric gliomas, 345
- Corona radiata, injury of, in insular surgery, 204
- Cortical stimulation mapping, for eloquent gliomas, 216–219
- Craniotomies, for multifocal and multicentric gliomas, 345
- CT-322, 338
- Cushing, Harvey, on brain function, 216

D

- Dasatinib, 347
- DC101 antiangiogenesis factor, 346
- Dendritic cell vaccines, 347–348
- 3'-Deoxy-3'-18F-fluorothymidine, for determining treatment response, 284
- Diffusion tensor imaging
 - for eloquent gliomas, 220–221
 - for multifocal and multicentric gliomas, 344
 - for pseudoprogression, 283
 - for surgical planning, 261
- Diffusion-weighted imaging
 - for determining treatment response, 274
 - for pseudoprogression, 282–283

Direct cortical stimulation mapping, for eloquent gliomas, 216–219

DNA repair, 247–248, 250

Dynamic susceptibility contrast-enhanced perfusion imaging

for multifocal and multicentric gliomas, 344

for pseudoprogression, 283

Dysarthria, after insular glioma resection, 204

Dysphasia, after insular glioma resection, 204

E

EGFR (epidermal growth factor receptor) and variant III, 237–240, 347

Electrocortical stimulation mapping, for eloquent gliomas, 216–219

Electrode treatment (NovoTTF-100A system), 315–316

Endothelial cells, radiation necrosis of, 279–281

EORTC (European Organisation for Research and Treatment of Cancer), 241, 260

Epidermal growth factor receptor and variant III, 237–240, 347

Epilepsy. *See* Seizures.

Erlotinib, 238, 347

European Organisation for Research and Treatment of Cancer (EORTC), 241, 260

External beam radiation, 260

F

Facial palsy, after insular glioma resection, 204

Ferrier, David, on brain function, 216

FK866, 314

18F-Fluorodeoxyglucose

for determining treatment response, 274–275

for pseudoprogression, 284

18F-Fluoroethyltyrosine, for determining treatment response, 275

18F-Fluorothymidine, for determining treatment response, 275

Focal adhesion kinase, 347

Foerster, Otfried, on brain function, 216

Folkman model of angiogenic switch, 332

Fotemustine, 304

Fractionated radiation therapy, 251–252, 263–265

Fritsch, Gustav, on brain function, 216

G

Gall, Franz Joseph, on phrenology, 216

Gamma Knife radiosurgery, 264

Gefitinib, 238, 347

Gliadel (BCNU, carmustine) polymer wafers, **289–295**, 302–303, 315–316

Glioblastoma

bevacizumab for, **331–341**

radiation therapy for, 263–266

surgical treatment for, nihilism in, 207–214

treatment of, pseudoprogression after, 271–272, **277–278**

Glioblastoma multiforme

supraselective intra-arterial cerebral infusion for,

323–329, 338–339

temozolomide for, **307–322**

Gliomas, high-grade. *See* High-grade gliomas.

H

Hemiparesis, after insular glioma resection, 204

Hemiplegia, after insular glioma resection, 204

Hemispherectomy, outcome of, 208

High linear energy transfer-charged particle therapy, with carbon ions, 263

High-grade gliomas

anatomy of, 199–200

clinical characteristics of, 200–201, 203

diagnosis of, 200–201, 203

insular, **199–206**

mapping of, **215–225**, **237–246**

pathogenesis of, **237–246**

recurrent. *See* Recurrent disease.

seizures in, **227–235**

treatment of

chemotherapy for. *See* Chemotherapy.

historical views of, **207–214**

insular, 200, 202–204

multifocal and multicentric, **348–350**

nihilism in, **207–214**

nonsurgical, 204–205

prognosis for, **207–214**

pseudoprogression after, 271–272, **277–287**

radiation therapy. *See* Radiation therapy.

response to, **269–276**

Hitzig, Eduard, on brain function, 216

Hyperbaric oxygen, as radiosensitizer, 250, 263

Hyperfractionation, in radiation therapy, 249

Hyperradiosensitivity, 265–266

Hypofractionated stereotactic radiotherapy, 265–266

I

Imatinib, 238

Immunotherapy

for multifocal and multicentric gliomas, 348

temozolomide with, 313

Insular gliomas, **199–206**

anatomy of, 199–200

clinical characteristics of, 200–201, 203

diagnosis of, 200–201, 203

nonsurgical treatment of, 204–205

surgical treatment for, 200, 202–204

Integrins, 315

Intensity-modulated radiotherapy, 251–252

Interferon- β , 314
 Intra-arterial cerebral infusions, **323–329**, 338–339
 Invasion, tumor, drugs targeting, 316–317
 Irinotecan, 298–300

J

Jackson, John Hughlings, on brain function, 216

K

Karnofsky Performance Status, for radiation therapy prediction, 251

L

Lamotrigine, for seizures, 230–231
 Lapatinib, 238
 Lenticulostriate arteries, injury of, in insular surgery, 204
 Levetiracetam, for seizures, 230–231
 Levin criteria, for determining treatment response, 270
 Linear-quadratic modeling, in radiation therapy, 248–249
 Lomustine (CCNU), 289, 300–302
 Lymphopenia, temozolimide-induced, 310

M

Macdonald criteria, for determining treatment response, 270–272, 282, 335–336
 Magnetic resonance imaging
 for determining treatment response, 269–274
 for insular gliomas, 203
 for multifocal and multicentric gliomas, 344
 for pseudoproggression, 277–283
 for surgical planning, 261–262
 functional, for eloquent gliomas, 219–220
 Magnetic resonance perfusion, for determining treatment response, 273–274
 Magnetic resonance permeability, for determining treatment response, 274
 Magnetic resonance spectroscopy
 for determining treatment response, 274
 for pseudoproggression, 282, 283
 Magnetoencephalography, for eloquent gliomas, 220
 Mapping, for eloquent gliomas, **215–225**
 Margins, in glioma surgery, 210–212
 Marimastat, 347
 Matrix metalloproteinase inhibitors, 347
 Medical Research Council trials, of radiation therapy, 260
 Memory deficits, after insular glioma resection, 204
 ^{11}C -Methionine PET
 for determining treatment response, 275
 for surgical planning, 261–262

Methoxyamine, 314
 O⁶-Methylguanine-DNA methyltransferase (MGMT), 241–242, 278, 301, 304
 Metronidazole, as radiosensitizer, 250
 MGMT (O⁶-methylguanine-DNA methyltransferase), 241–242, 278, 301, 304
 Misonidazole, as radiosensitizer, 250
 Motor mapping, for eloquent gliomas, **215–225**
 Multifocal and multicentric gliomas
 definition of, 343–344
 diagnosis of, 344–345
 epidemiology of, 343
 pathogenesis of, 344
 pathology of, 344
 prognosis for, 348
 treatment of, 345–348

N

National Cancer Institute, radiation trials of, 260
 Necrosis, radiation, 278–281, 339
 Nihilism, in glioma surgery, **207–214**
 Nimotuzumab, 230–231
 Nimustine, 263
 Nitroimidazoles, as radiosensitizers, 250
 Nitrosoureas, 300–303
 NovoTTF-100A system, 315–316

O

Observational mapping, for eloquent gliomas, 219–221
 Oligodendrocytes, radiation necrosis of, 279–281
 Oxcarbazepine, for seizures, 231
 Oxygen-mediated radiosensitization, 250

P

Palliative treatment, radiation for, 253
 Pediatric patients, PTEN mutations in, 315
 Penfield, Wilder, on brain function, 216
 Perivascular niche, in radiation therapy, 248–249
 PET. *See* Positron emission tomography.
 Phenytoin, for seizures, 230–231
 Phosphatase and tensin homolog deleted on chromosome 10 (PTEN), 240–241, 314
 Phosphokinase C/phosphatidylinositol 3-kinase/AKT pathways, 314–315
 Photon radiation, 260
 Poly (ADP-ribose) polymerase hyperactivation, 314
 Polymer wafers, of BCNU, **289–295**, 302–303, 315–316
 Positron emission tomography
 for determining treatment response, 274–275
 for eloquent gliomas, 220
 for pseudoproggression, 282, 284
 for surgical planning, 261–262

Procarbazine, 263
 Proton magnetic resonance spectroscopy, for pseudoprogession, 283
 Pseudoprogession, after treatment, 271–272, **277–287**
 antiangiogenic, 281–282
 definition of, 277–278
 mechanisms of, 278
 radiation, 277–281
 radiation necrosis and, 278–281
 response assessment criteria for, 282
 temozolimide and, 310–311
 versus true progression, 282–284
 Pseudoresponse, after treatment, 271–272
 PTEN (phosphatase and tensin homolog deleted on chromosome 10), 240–241, 314

R

Radiation necrosis, 278–281, 339
 Radiation therapy, **247–267**
 chemotherapy with, 263
 current paradigm for, 249–250
 delivery types for, 251–253
 extent of radiation in, 260
 for multifocal and multicentric gliomas, 345
 for recurrent glioma, 253
 for seizures, 229–230
 history of, 260–261
 hyperfractionation in, 249
 in multimodality therapy, 260–261
 palliative, 253
 radiation dose for, 249
 radiation sensitizers for, 250, 263
 radiation volume in, 249–250
 radiobiology of, 247–249
 radiosurgery, 204–205, 263–266
 response to, prediction of, 250–251
 sensitivity to, 263
 stereotactic surgery, 252, 263–266
 surgery with, 261
 techniques for, 261–263
 temozolomide with, 313
 Radiation Therapy Oncology Group trial, 249, 252
 Radiology, for determining response to treatment, 269–271, **269–276**
 current criteria for, 271–272
 emerging modalities for, 272–275
 historical criteria for, 269–271
 Radioresistance, 248–249
 Radiosensitivity, in radiation therapy, 248
 Radiosensitization, 250
 Radiosurgery, 204–205, 263–266
 RANO (Response Assessment in Neuro-Oncology) criteria, 269, 271–272, 335–336
 RECIST (Response Evaluation Criteria in Solid Tumors), 271–273

Recurrent disease
 bevacizumab for, **331–341**
 radiation therapy for, 253
 supraselective intra-arterial cerebral infusion for, **323–329**, 338–339
 Recursive partitioning analysis, for radiation therapy prediction, 251
 Redistribution, after radiation therapy, 248
 Reoxygenation, after radiation therapy, 248
 Repair, after radiation therapy, 247–248, 250
 Repopulation, after radiation therapy, 248
 Response Assessment in Neuro-Oncology (RANO) criteria, 269, 271–272, 335–336
 Response Evaluation Criteria in Solid Tumors (RECIST), 271–273
 Rilotumumab, 347
 Rolandic cortex, electrocortical mapping of, 218–219

S

Seizures, **227–235**
 characteristics of, 227–229
 in electrocortical mapping, 217
 in insular gliomas, 201, 203
 mechanisms of, 227–229
 predictors of, 227–229
 prevalence of, 227
 surgical treatment with, 229–230
 Sensitizers, radiation, 250, 263
 Sensorimotor impairment, after insular glioma resection, 204
 Sherrington, Charles, on brain function, 216
 Single-photon computed emission tomography, for surgical planning, 262
 Sirolimus, 238
 Somatosensory evoked potentials, for central sulcus identification, 218–219
 Sphingosine kinase inhibitors, 314
 Stem cells, radiation therapy effects on, 248–249
 Stem-like cells, drugs targeting, 347–348
 Stereotactic radiation therapy, 252, 263–266
 Stereotactic radiosurgery, 263–266, 345
 Stupp protocol, for pseudoprogession, 277
 Subventricular zone, drugs targeting, 347
 Sunitinib, 338
 Supraselective intra-arterial cerebral infusions, **323–329**

T

Temozolomide, 240, **307–322**
 BCNU with, 302
 CCNU with, 301
 dosage of, 311–313
 FDA-approved therapies with, 315–316
 for multifocal and multicentric gliomas, 345–346
 immunotherapy with, 313

- in combination therapy, 313–315
- in MGMT, 250
- in pseudoprogression, 277–279
- intra-arterial infusion of, **323–329**
- irinotecan with, 299–300
- mechanism of action of, 309–310
- quality of life issues with, 310–311
- radiation therapy with, 260–262, 313
- resistance to, 241–242, 313–315
- scheduling of, 311–313
- side effects of, 310–311
- Tenascin C, 346–347
- Thalidomide, 338
- Three-dimensional conformal radiotherapy, 251–252
- Topiramate, for seizures, 230–231
- Transcortical approach, to insular gliomas, 200, 202, 204
- Transcranial stimulation, for cental sulcus identification, 219
- Transopercular approach, to insular gliomas, 202
- Trans-sylvian approach, to insular gliomas, 200, 202
- Tumor cell dissemination story, 208–210
- Tumor growth factor β , 346

U

- Uncinate fasciculus, injury of, in insular surgery, 204

V

- Vaccines
 - dendritic cell, 347–348
 - epidermal growth factor in, 240
- Valproic acid, for seizures, 230–231
- Vascular endothelial growth factor
 - in angiogenesis, 332–333
 - in radiation necrosis, 279–281
- Vatalanib, 338
- Vincristine, 263
- Vogt, Oscar and Cécile, on brain function, 216

W

- Wafers, BCNU-containing, **289–295**, 315–316
- Whole brain radiotherapy, for multifocal and multicentric gliomas, 345
- World Health Organization oncology response criteria, for determining treatment response, 270

X

- XL 184, 338

Z

- Zonisamide, for seizures, 232